Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NC525 in advanced myeloid neoplasms
NCT05787496Phase 1Terminated
- Sponsor
- NextCure, Inc.
- Start
- Feb 2023
- Primary completion
- Jan 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of NC525 in acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML) and myelodysplastic syndrome (MDS) (6 arms), sponsored by NextCure, Inc. Primary endpoints: Treatment-emergent Adverse Events at 23 months and Dose-limiting Toxicities at 56 days. Started Feb 2023; status: terminated.
02
Drugs
NC525
03
Conditions
acute myeloid leukemia (AML)chronic myelomonocytic leukemia (CMML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05787496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05787496.